Ten30 Biosciences — General Support
Verified$5M
Funder
Recipient
Ten30 Biosciences
Date
Apr 2025
Data source
Source
Notes
[Scientific Research] Open Philanthropy recommended an investment of $5,000,000 in Ten30 Biosciences for general support. Ten30 Biosciences is a biotechnology company that is developing a novel oral drug to treat sickle cell disease, using an in-house platform that leverages AI and chemistry to discover therapeutics for challenging diseases. This falls within our focus area of scientific research.
Other Grants by Coefficient Giving
2625| Grant | Recipient | Amount | Date |
|---|---|---|---|
| Janaagraha — Air Quality Grants Assessment | $195K | Dec 2024 | |
| Futurewise — Housing Advocacy in Washington | $450K | Apr 2023 | |
| Exscientia — Agonists for Interferon Lambda | $2.3M | Sep 2023 | |
| Kurzgesagt — Short-form Video Content | $3M | Mar 2022 | |
| Kurzgesagt — Video Production (2023) | $1.7M | May 2023 | |
| Kurzgesagt — Video Creation and Translation | $2.6M | Dec 2021 | |
| Lightcone Infrastructure – General Support | Lighthaven (Event Venue) | $4.5M | Sep 2022 |
| Lightcone Infrastructure — General Support (2023) | Lighthaven (Event Venue) | $3M | Oct 2023 |
| Conjecture — Cybersecurity Bootcamp | Conjecture | $223K | Jun 2025 |
| Conjecture — AI Safety Technical Program | Conjecture | $224K | May 2023 |
Showing 10 of 2625 grants